Prevention of Clostridium difficile Infection
This study will assess the safety and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI with metronidazole or oral vancomycin. The objectives of this study are to:
- Evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for CDI.
- Characterize the frequency and duration of stool colonization with the VP 20621 strain of C. difficile.
- Evaluate the efficacy of VP 20621 for prevention of recurrence of CDI.
- Select a dose regimen of VP 20621 to be used in future studies.
Approximately 240 subjects will participate in the study from 50 sites in North America and Europe. The Reading Hospital has completed enrollment in this study, but it continues to conduct follow-up visits with the patients who are already enrolled. For more information, please call the Clinical Trials Office at 610-988-4308 or visit clinicaltrials.gov.